Abstract
In spite of optimal treatment of LDL - cholesterol, as per evidence -based guidelines, only a one third reduction in cardiovascular risk is achieved in our patients. This has led to the realization that other types of cholesterol, too, need to be treated, in order to achieve ideal cardiovascular health. The review focuses on high density lipoprotein (HDL) cholesterol as a target for treatment, its importance, relevant patents and current as well as future treatments.
Keywords: HDL cholesterol, hyperlipidemia, niacin, fibrates, statins
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
Title: HDL - Cholesterol: The New Target for Treatment
Volume: 4 Issue: 2
Author(s): Sanjay Kalra, Bharti Kalra, Navneet Agrawal and Ashraf Ganie
Affiliation:
Keywords: HDL cholesterol, hyperlipidemia, niacin, fibrates, statins
Abstract: In spite of optimal treatment of LDL - cholesterol, as per evidence -based guidelines, only a one third reduction in cardiovascular risk is achieved in our patients. This has led to the realization that other types of cholesterol, too, need to be treated, in order to achieve ideal cardiovascular health. The review focuses on high density lipoprotein (HDL) cholesterol as a target for treatment, its importance, relevant patents and current as well as future treatments.
Export Options
About this article
Cite this article as:
Kalra Sanjay, Kalra Bharti, Agrawal Navneet and Ganie Ashraf, HDL - Cholesterol: The New Target for Treatment, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 2010; 4 (2) . https://dx.doi.org/10.2174/187221410791196605
DOI https://dx.doi.org/10.2174/187221410791196605 |
Print ISSN 1872-2148 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3334 |
Related Articles
-
Ultrasound Contrast Agents: Updated Data on Safety Profile
Current Pharmaceutical Design Beyond Cholinesterase Inhibition: Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets The Contribution of Mannose Binding Lectin to Reperfusion Injury after Ischemic Stroke
Current Neurovascular Research Anti-HIV Drug Development: Structural Features and Limitations of Present Day Drugs and Future Challenges in the Successful HIV/AIDS Treatment
Current Pharmaceutical Design Opportunities for Nano-Formulations in Type 2 Diabetes Mellitus Treatments
Current Pharmaceutical Biotechnology Histone Methylation and Transcriptional Regulation in Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Endotoxin, TLR4 Signaling and Vascular Inflammation: Potential Therapeutic Targets in Cardiovascular Disease
Current Pharmaceutical Design Novel Approach to Cardiovascular Diseases: A Promising Probability of (Pro)Renin Receptor [(P)RR]
Current Pharmaceutical Design Is the Carotid Plaque Rupture a Pivotal Event in Stroke Pathogenesis? Update on the Role of the Intraplaque Inflammatory Processes
Current Vascular Pharmacology Herbal Medicine for Slowing Aging and Aging-associated Conditions: Efficacy, Mechanisms and Safety
Current Vascular Pharmacology Recent Patents on Biomedical Applications for the Treatment of Atherosclerosis
Recent Patents on Regenerative Medicine The Role of Neopterin in Atherogenesis and Cardiovascular Risk Assessment
Current Medicinal Chemistry Inhibition of Candida rugosa Lipase by Different Extracts of Five Algerian Plants and their Antioxidant Activities
Current Enzyme Inhibition Mitochondrial Triglyceride Transfer Protein Inhibition: New Achievements in the Treatment of Dyslipidemias
Current Pharmaceutical Design Flavonoids and the Brain: Evidences and Putative Mechanisms for a Protective Capacity
Current Neuropharmacology Management of Peyronie's Disease after Collagenase (Xiaflex:<sup>®</sup>)
Current Drug Targets Current Understanding of Dietary Polyphenols and their Role in Health and Disease
Current Nutrition & Food Science Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets
Current Pharmaceutical Design GDF 15 - A Novel Biomarker in the Offing for Heart Failure
Current Cardiology Reviews Having a Promising Efficacy on Type II Diabetes, It’s Definitely a Green Tea Time
Current Medicinal Chemistry